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Context: The sympathetic nervous system (SNS) controls bone turnover in rodents, but it is uncer-
tain whether a similar role for the SNS exists in humans. Pheochromocytomas are catecholamine-
producing neuroendocrine tumors. Because catecholamines are the neurotransmitters of the SNS,
we hypothesized that pheochromocytoma patients have increased bone turnover.
Objective: Our objective was to compare bone turnover in pheochromocytoma patients and
controls.
Design and Setting: This retrospective case-control study was performed at the Endocrine Depart-
ment of the Academic Medical Center of the University of Amsterdam in The Netherlands from
2007 until 2011.
Patients:All patientswere screened for pheochromocytoma. Cases (n21)were identifiedby 24-h
urinary excretion of fractionated metanephrines above the institutional reference value and con-
firmed by histology after adrenalectomy. All patients screened and diagnosed as not having pheo-
chromocytoma served as controls (n  126).
Main Outcome Measure: The difference in bone turnover markers C-terminal cross-linking telo-
peptides of collagen type I (CTx) and procollagen type 1 N propeptide (P1NP) between cases and
controls was the main outcome measure.
Results: CTx concentrations were higher in cases [343 ng/liter; interquartile range (IQR), 295 ng/
liter] than in controls (232 ng/liter; IQR, 168 ng/liter; P 0.001) and decreased after adrenalectomy
[before, 365 ng/liter (IQR, 450 ng/liter); after, 290 ng/liter (IQR, 241 ng/liter); P 0.044]. The effect
remained after adjustment for possible confounders. P1NP concentrations did not differ.
Conclusions: This study shows that pheochromocytoma patients have increased bone resorption,
which normalizes after adrenalectomy. This finding supports the concept of regulation of bone
remodeling by the SNS in humans. (J Clin Endocrinol Metab 97: E2093–E2097, 2012)
In the last decade, the sympathetic nervous system (SNS)has been identified as an important regulator of bone
turnover in mice (1). Disruption of sympathetic signaling
by deletion of the adrenergic -2 receptor leads to a high
bone mass phenotype (2). In addition, pharmacological
manipulation of the SNS by administration of -blockers
or -agonists induces an increase and a decrease, respec-
tively, in bone mass (3–6).
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Whether this “central control” of bone metabolism
also holds true for humans remains a question. Several
retrospective case-control and cohort studies have inves-
tigated the risk of fracture during -blocker treatment,
and whereas some showed a reduction in fracture risk,
others found no change. A meta-analysis did show an
overall reduction in fracture risk (7). For -agonist
treatment, three studies failed to demonstrate an effect
on fracture risk in patients with chronic obstructive pul-
monary disease (8–10). The observational nature of
these studies, however, makes it difficult to draw any
definite conclusions.
To study the effect of sympathetic stimulation on bone
in humans,we investigated bonemetabolism in pheochro-
mocytoma patients. Pheochromocytomas are catechol-
amine-producing neuroendocrine tumors (11). Norepi-
nephrine, a catecholamine, is themainneurotransmitterof
the SNS. We hypothesized that pheochromocytoma pa-
tients would have an increase in bone turnover resulting
from sympathetic overstimulation. Therefore, we con-
ducted a case-control study comparing bone turnover
markers in pheochromocytoma patients and controls.
Patients and Methods
Study design and setting
This retrospective case-control study was performed at the
Endocrine Department of the AcademicMedical Center (AMC)
of the University of Amsterdam in TheNetherlands. All patients
screened for pheochromocytoma in 2007 and 2008 were in-
cluded in the study; the inclusion of case patients was extended
to 2009, 2010, and 2011. The screening protocol for pheochro-
mocytoma was carried out as reported before (12). The Institu-
tional Review Board of the AMC approved this study.
Study population
Patientswerebiochemically screened forpheochromocytoma
because of: 1) symptoms and signs suggesting pheochromocy-
toma;2) adrenal incidentaloma;or3) agenetic predisposition for
pheochromocytoma (multiple endocrine neoplasia type 2 or suc-
cinate dehydrogenase complex subunit D mutation). Patients
with a history of pheochromocytoma, pregnancy, alcohol or
drug abuse, or age under 18 yr were excluded.
Screening consisted of measurement of 24-h urinary excre-
tion of fractionatedmetanephrines. Patients withmeasured con-
centrations above the institutional age-adjusted reference value
underwent imaging of the adrenal gland. The diagnosis of pheo-
chromocytomawas confirmedbyhistologyafter adrenalectomy,
and these patients were defined as cases. All other patients were
defined as controls.Age, sex, length,weight, smoking status, and
medication use of all patients were recorded.
Analytical procedures
C-terminal cross linking telopeptides of collagen type I
(CTx) and procollagen type 1 N propeptide (P1NP) are pa-
rameters reflecting bone resorption and bone formation, re-
spectively, and they were the main outcome measures. CTx
and P1NP were measured using immunoassays (Modular
Analytics E 170; Roche Diagnostics Corporation, Indianap-
olis, IN; and Orion Diagnostica, Espoo, Finland, respec-
tively), as described earlier (13).
To establish the diagnosis of pheochromocytoma, urinary
metanephrines and normetanephrines were measured. Urine
samples were acidified to pH 2, boiled for 30 min, and
diluted in pasteurized plasma protein solution (Albuman; San-
quin, Amsterdam, The Netherlands). Thereafter, urine sam-
ples were analyzed as plasma samples, and the fractionated
metanephrines were determined by automated online solid-
phase extraction HPLC-tandem mass spectrometry as de-
scribed by de Jong et al. (14).
All measurements were performed on serum samples col-
lected in the morning after an overnight fast, following the stan-
dardized protocol during the pheochromocytoma screening
(12), and stored at20 C until assayed. For some case patients,
measurements were repeated after adrenalectomy following the
same protocol.
Statistical analysis
The statistical analysis was done using PASW Statistics for
Windows, version 18.0 (SPSS Inc., Chicago, IL). The mean and
SD or the median and interquartile range (IQR) are reported de-
pending on the distribution. Differences between cases and con-
trolswere tested using theMann-WhitneyU test, and differences
before and after adrenalectomy using the Wilcoxon signed rank
test because the bone turnover markers follow a skewed distri-
bution. Bone turnovermarkerswere log-transformed to perform
multiple linear regression analysis to test for confounding and
effect modification by interaction. Assumptions underlying the
linear regression model were met. All tests were two-sided, and
a P value 0.05 was considered significant.
Results
Patients
During 2007 and 2008, 180 patients were screened for
pheochromocytoma. The blood samples of 36 patients
couldnotbe retrieved.Tenpatientswere excludedbecause
of a history of pheochromocytoma. Eight cases were iden-
tified, and the remaining 126patientswere controls. From
2009 to 2011, 13 additional cases were identified; there-
fore, the total number of cases is 21. In all cases, the di-
agnosis was confirmed by pathological examination after
surgery. Characteristics of the cases and controls are
shown in Table 1. Cases and controls were comparable,
except for the 24-h urinary (nor)metanephrines secretion.
Bone turnover markers and pheochromocytoma
CTx concentrations were higher in cases than in con-
trols [343ng/liter (IQR,295ng/liter) vs.232ng/liter (IQR,
168 ng/liter); P 0.001] (Fig. 1A).Multiple linear regres-
sion analysis confirmed the association between pheo-
chromocytoma and CTx after adjustment for age, sex,
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bodymass index, smoking status, andmedication use (thi-
azide diuretics, glucocorticoids, hormonal replacement
therapy, bisphosphonates, and -blockers) (model: con-
stant 2.378; pheochromocytomaB0.2030.058 SE, 95%
confidence interval 0.088–0.318; P  0.001). Of these
possible confounders, only the use of -blockers (n 33)
and bisphosphonates (n  3) were significant predictors
for CTx. -Blocker users had a lower median CTx con-
centration [200 ng/liter (IQR, 164 ng/liter)] than nonusers
[297 ng/liter (IQR, 202 ng/liter); P  0.005].
P1NP concentrations did not differ between cases and
controls [cases, 45 g/liter (IQR, 43 g/liter) vs. controls,
41 g/liter (IQR, 24 g/liter); P 0.408] (Fig. 1B). Mul-
tiple linear regression analysis did not show any other
significant predictors for P1NP.
Adrenalectomy
In 16 pheochromocytoma patients, a blood sample
after adrenalectomy was available. CTx concentrations
decreased after adrenalectomy from 365 ng/liter (IQR,
450 ng/liter) to 290 ng/liter (IQR, 241 ng/liter) (P 
0.044) (Fig. 1C). After adrenalectomy, CTx concentra-
tions were no longer different from controls. P1NP con-
centrations did not change after adrenalectomy [before
adrenalectomy, 41 g/liter (IQR, 35 g/liter); after ad-
renalectomy, 35 g/liter (IQR, 20 g/liter); P  0.623]
(Fig. 1D).
Discussion
This study shows that pheochromocy-
toma patients have increased bone re-
sorption, which normalizes after adre-
nalectomy. This finding supports the
concept of regulation of bone remodel-
ing by the SNS in humans.
Previous experiments in mice have
shown that activation or inhibition of
the SNS influences bone metabolism
and that this effect is mediated by the
-2 adrenergic receptor on the osteo-
blast (2). Pharmacological stimulation
of the-2 adrenergic receptor increases
bone resorption and decreases bone
formation leading to a low bone mass,
whereas inhibition of the receptor has
the opposite effect (3–6).
In humans, the-2 adrenergic recep-
tor is expressed by bone cells (3, 15).
Human studies on the role of the SNS in
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FIG. 1. A and B, Plasma CTx and P1NP in patients with pheochromocytoma and controls. C
and D, Plasma CTx and P1NP in patients with pheochromocytoma before and after
adrenalectomy.
TABLE 1. Patient characteristics
Controls Cases P value
n 127 21
Sex (% male) 39 48 0.476
Age, mean (SD) (yr) 59 (14) 55 (12) 0.266
Body mass index, mean (SD) (kg/m2) 27.3 (4.8) 24.2 (3.6) 0.007
Smoking (%) 35 38 0.729
Medication use (%)
Corticosteroid 2 0 0.475
Hormonal replacement therapy 6 5 0.882
Bisphosphonate 3 0 0.408
Thiazide diuretic 22 33 0.268
-blocker 24 14 0.333
Normetanephrine excretion in 24-h urine, median (IQR) (mol) 1.63 (0.99) 5.74 (15.28) 0.001
Metanephrine excretion in 24-h urine, median (IQR) (mol) 0.45 (0.31) 2.66 (22.5) 0.001
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bone remodeling have focused primarily on the associa-
tion between fracture risk and the use of -blockers.Most
-blockers are selective for the -1 adrenergic receptor,
which makes it difficult to interpret the conclusions from
these studies. Some attempts have been made to study the
effect of-agonists onbone remodeling inhumans, but the
results of these studies were all negative. These studies
were carried out in patients with chronic obstructive pul-
monary disease. The negative results are likely explained
by the use of -2 agonists as inhalers, which limits the
systemic availabilitynecessary to reachbone tissue; theuse
of corticosteroids as co-medication,whichmayhave over-
whelmed the effect of-2agonists onbone; and finally, the
severity of the pulmonary disease that may have con-
founded the results (8–10).
Toovercome theseobjections,we searched for ahuman
model of disease in which the -2 adrenergic receptor is
implicated. Pheochromocytomas produce excess cat-
echolamines capable of stimulating the -2 adrenergic re-
ceptor. Therefore, we hypothesized that the catechol-
amine excess in pheochromocytoma patients could
stimulate bone turnover in humans, as was confirmed in
this study.Adrenalectomy, the surgical removal of the cat-
echolamine-producing tumor, relieves the catecholamine
excess, and this was indeed accompanied by a normaliza-
tion of bone resorption. Therefore, the present study en-
dorses the hypothesis that the SNS exerts a control over
bone metabolism in humans.
During physiological bone remodeling, bone resorp-
tion and bone formation are coupled, securing the balance
in bonemass.Many pathological bone conditions, such as
osteoporosis and osteopetrosis, are characterized by un-
coupling of bone resorption and formation, leading to a
loss or gain in bone mass (16). Uncoupling was also ob-
served in the adrenergic-2 receptor knockoutmice (2). In
the present study, we also observed uncoupling of bone
formation and resorption becausewe found an increase in
CTx, the bone resorption marker, but no difference in
P1NP, the bone formation marker. This suggests that
in pheochromocytoma patients, uncoupling of bone re-
sorption and bone formation takes place, ultimately lead-
ing to a decrease in bonemass.Unfortunately, because this
was a retrospective study, we were not able to assess the
bonemass in these patients. For future studies, it would be
interesting to assess bone mass changes by dual-energy
x-ray absorptiometry scanning in pheochromocytomapa-
tients during disease and after recovery.
A potential limitation of this study is the use of a
single marker for bone resorption (CTx) and formation
(P1NP). Possibly, our result could have been strength-
ened by the addition of multiple makers. However, CTx
and P1NP are recommended as the preferred reference
markers for bone resorption and formation in clinical
studies by the International Osteoporosis Foundation
and the International Federation of Clinical Chemistry
and Laboratory Medicine because CTx and P1NP are
the most specific for bone compared with the other
markers and because of the wide availability of an au-
tomated assay that has been well characterized, en-
abling comparison among different studies (17).
We included 126 control patients, yet only 21 cases
were collected, 16 of which had blood samples taken be-
fore and after adrenalectomy. This limitation reflects the
rare nature of the disease.However, 21 cases yield enough
statistical power to conclude that there is a difference in
bone resorption in cases compared with controls.
Our data suggest that it is the catecholamine excess
resulting in sympathetic overstimulation that causes the
increase in bone resorptionbecausewehave accounted for
many possible confounding factors such as age, sex, body
mass index, smoking. and medication use. However, we
cannot exclude the possibility that there are other con-
founding factors in pheochromocytoma patients that we
have not accounted for. We have tried to minimize this
possibility by including control patients from the same
screening cohort as the pheochromocytoma patients in-
stead of including healthy controls, making them as com-
parable as possible. Of course, future studies in other co-
horts will be needed to confirm our results.
To summarize, this study supports the concept of sym-
pathetic control of bone remodeling in humans by dem-
onstrating an increased bone resorption in pheochromo-
cytoma patients that normalizes after adrenalectomy.
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